Christoph Huber
Angel Investor
Mainz, Germany
Christoph Huber is a Series A investor in Mainz focused on Medical and Biotechnology. After his studies at Medical School of the Leopold Franzens University in Innsbruck,Christoph Huber gained experience as a health professional of internal medicine and received his Ph.D. Several research scientist visits (Dept. Tumor Biology of Karolinska Institute, Stockholm, Wallenberg Laboratorium, Dept. Immunology of Uppsala University) were followed by an education in clinical bone marrow transplantation at the Fred Hutchinson Cancer Research Center, Seattle. Back in Innsbruck, Huber headed the bone marrow transplantation section of the Department of Internal Medicine, eventually becoming Professor of Clinical Immunobiology. Huber is Emeritus Professor of Medicine at the Medical School of the Johannes Gutenberg University in Mainz, co-founder and board member of the Translational Oncology research organization and co-founder and Head of Supervisory Board at the Cluster for individualized immune intervention (CI-3). Huber also co-founded the biopharmaceutical companies Ganymed Pharmaceuticals and BioNTech and serves on both of their boards. Huber is a member of numerous scientific committees, in particular the international Association of Cancer Immunotherapy (CIMT), which he co-founded and chairs. Huber is the author of more than 250 publications, among them various articles in “Nature”, “Nature Immunology”, “Immunity”, and the “Journal of Experimental Medicine”.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Christoph Huber invests in
Stages Christoph Huber invests in
Countries Christoph Huber invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines. | $27M / Series A / Oct 06, 2026 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christoph Huber invest in?
Christoph Huber invests primarily in Medical and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christoph Huber?
Public channels for Christoph Huber include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christoph Huber last invest?
The most recent investment recorded for Christoph Huber closed in Oct 2026. Shizune tracks 1 investment in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
